FDA

FDA Articles

Tonix Pharmaceuticals saw its shares make a solid gain to start off the week after the company announced an update from the FDA regarding its Alzheimer’s agitation treatment.
The FDA issued a warning early on Friday that consumers should be on the lookout for criminals forging FDA warning letters.
Acceleron Pharma shares dipped on Friday after the company provided an update on an orphan drug designation from the FDA.
Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates in July.
Nuvectra shares were crushed on Monday after the company announced an update on its FDA premarket approval application and its TÜV SÜD application for CE Mark in Europe for Virtis.
Merck shares retreated to start off the week despite the announcement of good news from the FDA.
Here are a few biotech and pharmaceutical companies to watch for in the coming week and for the month of July.
A few biopharma stocks made massive runs over the course of this past week, some losing more than half their cap. Not all these moves were negative, but the overall sentiment was negative.
Dermira shares made a solid gain to close out the week after the firm announced a key approval from the FDA for Qbrexza (glycopyrronium) cloth.
Achaogen shares were crumbling on Tuesday following some mixed news from the FDA regarding its treatment of urinary tract and bloodstream infections.
Worries about a trade war continue to batter stocks worldwide, suits over climate change were decided in favor of big oil, and other important headlines.
GW Pharmaceuticals on Monday received approval from the U.S. FDA for its epilepsy drug derived from the marijuana plant. This is the first drug of its kind to receive FDA approval.
Tandem Diabetes Care shares made a solid gain early on Friday after the firm announced a key approval from the FDA.
For many drug developers, Parkinson’s disease is a tricky disease to treat. However, developing a treatment ultimately could yield a huge reward as there are currently no therapies that effectively...
Solid Biosciences watched its shares surge to kick off the week after the FDA lifted the clinical hold on its treatment for Duchenne muscular dystrophy.